Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial
| Autor: | R, Hitt, L, Iglesias, A, López-Pousa, A, Berrocal-Jaime, J J, Grau, C, García-Girón, J, Martínez-Trufero, M, Guix, J, Lambea-Sorrosal, E, Del Barco-Morillo, X, León-Vintró, A J, Cunquero-Tomas, N, Baste, A, Ocaña, J J, Cruz-Hernández |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Hypopharyngeal Neoplasms
Squamous Cell Carcinoma of Head and Neck Chemoradiotherapy Docetaxel Induction Chemotherapy Progression-Free Survival Intention to Treat Analysis Tumor Burden Treatment Outcome Clinical Trials Phase III as Topic Head and Neck Neoplasms Antineoplastic Combined Chemotherapy Protocols Confidence Intervals Humans Mouth Neoplasms Taxoids Fluorouracil Cisplatin Laryngeal Neoplasms Follow-Up Studies Randomized Controlled Trials as Topic Retrospective Studies |
| Zdroj: | Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 23(4) |
| ISSN: | 1699-3055 |
| Popis: | Our previous phase-3 study (TTCC 2503) failed to show overall survival advantage of 2 induction chemotherapy (IC) regimens followed by standard concurrent chemoradiotherapy (CRT) over CRT alone in patients with unresectable locally advanced head and neck squamous-cell carcinoma (LAHNSCC). This study described the long-term survival of those patients.Long-term follow-up study of patients with untreated LAHNSCC assigned to IC (three cycles), with either docetaxel, cisplatin and 5-fluorouracil (TPF arm) or cisplatin and 5-fluorouracil (PF arm), followed by CRT, or CRT alone, included in the previous TTCC 2503 trial.In the intention-to-treat population (n = 439), the median OS times were 25.4 (95% CI, 16.8-34.4), 26.2 (95% CI, 18.2-36.6) and 25.4 months (95% CI, 17.4-36.0) in the TPF-CRT, PF-CRT and CRT arms, respectively (log-rank p = 0.51). In the per-protocol population (n = 355), patients with larynx-hypopharynx primary tumors treated with IC (TPF or PF) followed by CRT had a longer median PFS than those who received CRT alone. Moreover, patients with ECOG 0 treated with IC (TPF or PF) followed by CRT had a better TTF than those with CRT alone. There were no statistically significant differences in terms of OS, PFS or TTF, according to the tumor load or affected nodes.After a long follow-up, the TTCC 2503 trial failed to show the benefit of IC-CRT in unresectable LAHNSCC regarding the primary end point. However, fit patients with ECOG 0 and primary larynx-hypopharyngeal tumors may benefit from the use of IC if administered by an experienced team. ClinicalTrials.gov identifier NCT00261703. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink